Background: Toll-like receptors (TLRs) play a fundamental role in innate immunity through their capacity to recognize pathogen-associated molecular patterns. Also, TLRs that are expressed in T cells are reported to function as co-stimulatory receptors. However, the functional capacity of TLRs on CD4 T and CD8 T cells has not been directly compared.
Background: Toll-like receptors (TLRs) play a fundamental role in innate immunity through their capacity to recognize pathogen-associated molecular patterns. Also, TLRs that are expressed in T cells are reported to function as co-stimulatory receptors. However, the functional capacity of TLRs on CD4 T and CD8 T cells has not been directly compared.
Here we compared CD4 and CD8 T cell responses to TLR2 ligand plus TCR-mediated stimulation. Methods: TLR2 expression was analyzed on T cell subsets under naïve and alloantigen-primed conditions. We analyzed the effects of TLR2 co-stimulation on proliferation and survival of T cell subsets in vitro when stimulated with soluble anti-CD3 in the presence or absence of synthetic ligand Pam3CSK4. Results: TLR2 expression on CD8 T cells was induced following activation; this expression was much higher than on CD4 T cells. Thus, the molecule was constitutively expressed on Listeriaspecific memory CD8 T cells. Based on these expression levels, proliferation and survival were markedly elevated in CD8 T cells in response to the TLR2 co-stimulation by Pam3CSK4 compared with those in CD4 T cells. Conclusion: Our data show that TLR2 co-stimulation is more responsible for proliferation and survival of CD8 T cells than for that of CD4 T cells. 
INTRODUCTION
Toll-like receptors (TLRs) are primary sensor molecules that play an integral role in innate immunity via their capacity to recognize pathogen-associated molecular patterns that allow the detection of infection and inflammation (1) . TLR stimulation of dendritic cells (DCs) and macrophages promotes the production of pro-inflammatory cytokines and the up-regulation of MHC and co-stimulatory molecules, which leads to the induction of T cell-mediated adaptive immune responses (2) .
Although much of our knowledge of TLR function in the immune system comes from the study of innate immune cells, these molecules also are expressed in T cells. Early studies of TLRs in T cells have been conducted with CD4 T cells. Naïve human CD4 T cells express TLR2 after activation by TCR stimulation and TLR2 functions as a co-stimulatory receptor. Moreover, TLR2 also participates in the generation and maintenance of CD4 T cell memory (3). TLR3 and TLR9 ligand directly deregulate Bcl-xL in CD4 T cells, thus promoting survival (4) . CpG DNA-mediated co-stimulation in CD4 T cells proceeds through the MyD88-dependent PI-3 kinase signaling pathway (5) . According to a recent study, TLR2 stimulation activates Th1 effector cells without TCR stimulation through the enhanced activation of MAPKs. In contrast, no TLR affects the function of Th2 effector cells (6) .
Several studies have reported the co-stimulatory effects of TLR on CD8 T cells. TLR2 engagement on CD8 T cells decreases the activation threshold for co-stimulatory signals delivered by APC (7). Quigley et al. showed that direct TLR2-MyD88 signaling in CD8 T cells plays a critical role in clonal expansion and memory formation against vaccinia viral (VV) infection (8) . It has been also reported that MyD88-dependent signals are critical for survival of Lymphocytic choriomeningitis virus (LCMV)-specific CD8 T cells and sustained accumulation for viral clearance (9) . Furthermore, TLR2 engagement on cytotoxic T-lymphocytes (CTL) augments antitumor activity against established B16 melanoma tumors (10) .
Certain co-stimulatory molecules on activated T cells are known to primarily be involved in either the CD4 or CD8 T cell subset. For example, 4-1BB is preferentially involved in CD8 T cell-mediated immune responses (11) . In the present study, we compared the expression and function of TLR2 on CD4 versus (vs.) CD8 T cells, which have not been directly compared yet. However, we found that TLR2 co-stim-ulation is more responsible for CD8 T cells than for CD4 T cells. ) mice were provided by S. Akira (Osaka University, Osaka, Japan). All mice were used for the experiments at the age of 8∼10 weeks.
MATERIALS AND METHODS

Mice
Antibodies and reagents
The following antibodies were purchased from e-Bioscience (San Diego, CA) for flow cytometry: FITC-conjugated anti-mouse CD3 (145-2C11), TLR2 (6C2), and H-2 b (AF6-88.5);
PE-conjugated anti-mouse CD4 (GK1.5), CD8 (53-6.7), TLR2 (6C2), Bcl-2 (3F11), Bcl-xL (7B2.5), and IFN-γ (XMG1.2); PE-Cy5-conjugated anti-mouse CD4 (GK1.5) and CD8 (53-6.7); purified anti-CD16/32 (2.4G2) and purified anti-TLR2 (T2.5). LLO 91-99 pentamer was obtained from ProImmune (Oxford, UK). Purified anti-mouse CD3 (145.2C11) was obtained from BD Biosciences (San Jose, CA). Pam3CSK4 was purchased from Invivogen (Carlsbad, CA).
Cell preparation, culture, and in vitro proliferation assay Naïve T cells were isolated from spleen and lymph nodes of B6 using anti-CD90 (Thy1.2) magnetic beads (Miltenyi Biotech, Auburn, CA) after depletion of CD25 + cells. The cells were ＞97% CD3 T cells with a naïve phenotype. To prepare the CD4 T and CD8 T cells, CD11c + and CD25 + cells were first depleted using anti-CD11c and -CD25 magnetic beads to remove Treg and lymphoid dendritic cells and then the cells were isolated using anti-CD4 or -CD8 magnetic beads, respectively. The cells were ＞97% CD3 + CD4 + or CD8 + T cells with a naïve phenotype. In vivo generation of Listeria-specific memory CD8 T cells Balb/c mice were infected intravenously (i.v.) with 3000 colony-forming units (CFU) of live L. monocytogenes. On day 25, the mice were reinfected with 5000 CFU of live bacteria intraperitoneally (p. i.); 5 days later, LLO91-99-specific CD8 T cells were determined using LLO91-99 pentamer.
Flow cytometry
To measure the expression of TLR2, cells were first incubated with FcR blocker (2.4G2) to block nonspecific antibody binding and then stained with PE-anti-TLR2 and PE-Cy5-anti-CD4 or CD8 and analyzed on a FACSCalibur flow cytometer (BD Biosciences) using the CellQuest software. To measure cell proliferation, cultured cells were treated with BrdU (2 μg, Sigma) for 1 h and washed with PBS. The cells were fixed, permeabilized, treated with DNase I, and stained with FITC-anti-BrdU using a BrdU Flow kit according to the manufacturer's instructions. To analyze cell death, cells were stained with FITC-annexin V and 7-AAD. To stain Bcl-2 and Bcl-xL, the cells were fixed, permeabilized, and stained with PE-anti-Bcl-2 or -Bcl-xL mAb. To stain intracellular IFN-γ, cells were fixed, permeabilized using the Cytofix/Cytoperm kit (BD Bioscience) according to the manufacturer's instructions, and incubated with PE-anti-IFN-γ mAb.
RESULTS
TLR2 expression is preferentially induced on CD8 T cells vs. CD4 T cells
To assess the expression pattern of TLR2 on CD4 vs. CD8 T cells, we performed flow cytometric analysis on naïve and alloantigen-activated T cells. TLR2 was not expressed on either naïve CD4 or CD8 T cells before adoptive transfer into allogeneic recipient. Four days after transfer, alloantigen-activated responder T cells induced TLR 2 expression. However, the expression levels were much higher on CD8 T cells (45.7±4.8%) than on CD4 T cells (5.4±3.2%) (Fig. 1A) . Furthermore, Listeria-specific memory CD8 T cells constitutively expressed TLR2 (Fig. 1B) . These data indicate that TLR2 is preferentially expressed on CD8 T cells following activation.
TLR2 co-stimulation dominantly enhances CD8 T cell expansion more than CD4 T cell expansion
To test the effect of TLR2 co-stimulation on the proliferation of total T cells or CD4 vs. CD8 T cells, T cells were isolated as described in Materials and Methods and incubated with soluble anti-CD3 (anti-CD3s) in the presence or absence of TLR2 ligand Pam3CSK4. First, we observed that the co-stimulation of total T cells with Pam3CSK4 led to a seven-fold enhancement of anti-CD3-induced proliferation ( Fig. 2A) . We next evaluated the ratio of CD4 vs. CD8 T cells in the proliferative capacity of the total T cell population that was enhanced by TLR2 co-stimulation, and performed the BrdU incorporation assay. Fig. 2B shows that there were more CD8 T cells than CD4 T cells in the increased proliferative capacity of total T cells. To further confirm the direct effect of TLR2 signaling on T cell subsets, we isolated highly purified populations of naïve CD4 or CD8 T cells after the depletion of creased five-fold (Fig. 3) . Taken together, these results indicate that TLR2 co-stimulation is preferentially involved in CD8 T cell expansion rather than CD4 T cell expansion.
TLR2 co-stimulation elevates CD8 T cell survival more strongly than CD4 T cell survival To further assess the effect of TLR2 co-stimulation on the survival of CD4 vs. CD8 T cells, isolated naïve CD4 and CD8 T cells were stimulated with anti-CD3s in the presence or absence of Pam3CSK4. Survival was then detected by annexin V plus 7-AAD staining at 64 h following activation. Pam 3 CSK 4 increased the activated CD8 T cell survival from 12% to 40% (Fig. 4B) . However, the CD4 T cell survival was increased from 25% to 35% by TLR2 co-stimulation (Fig. 4A) . Members of the Bcl family are reported to be key mediators of activated T cell survival following TLR2 co-stimulation (4). Therefore, we compared the levels of these molecules following TLR2 ligand treatment of CD4 or CD8 T cells. We observed more significant increases in Bcl-xL protein in Pam 3 CSK 4 -treated CD8 T cells than in CD4 T cells. However, Bcl-2 protein levels were similar in CD4 and CD8 T cells (Fig. 4C) . These data indicate that TLR2 co-stimulation is preferentially involved in CD8 T cell survival versus that in CD4 T cells. Thus, it is associated with specific Bcl-xL up-regulation.
Specificity of TLR2 co-stimulation
To exclude the possibility that the effects caused by Pam 3 CSK 4 were non-specific, we tested the assay using anti-TLR2 monoclonal antibody, which was added to the culture before the stimulation. As shown in Fig. 5 , the enhanced proliferation with Pam 3 CSK 4 was completely reversed in both CD4 and CD8 T cells by anti-TLR2 treatment as was IFN-γ production. In addition, T cells purified from TLR2 -/-mice exhibited no response to Pam 3 CSK 4 in terms of either the proliferation (Fig. 5A) or the IFN-γ production (Fig. 5B) , indicating that Pam3CSK4 acts through TLR2-dependent signaling pathways.
DISCUSSION
TLR in T cells can function as a co-stimulatory molecule for both CD4 and CD8 T cell activation (12) . In this study, we have confirmed that the TLR2 ligand Pam 3 CSK 4 provides a direct potent co-stimulatory effect on TCR-mediated T cell proliferation. However, we found that TLR2 co-stimulation was biased toward CD8 T cells rather than CD4 T cells. For instance, the addition of Pam3CSK4 increased the anti-CD3-mediated proliferation of total T cells by 7-fold ( Fig. 2A) . In this increased proliferative capacity, CD8 T cells were found in a higher proliferative ratio than CD4 T cells (Fig. 2B) , which was confirmed on an isolated subset of T cells (Fig.  3) . We also observed that TLR2 co-stimulation promoted the survival of CD8 T cells more than that of CD4 T cells (Fig.  4A, B) . This was caused not by Bcl-2 but by increased BclxL (Fig. 4C ). In fact, the different sensitivity to TLR2 co-stimulation is probably related to the expression levels on CD4 versus CD8 T cells. The surface expression was more highly induced following activation on CD8 T cells compared with that on CD4 T cells (Fig. 1A) . Taken together, these results indicate that CD8 T cells preferentially respond to TLR2 co-stimulation. CD8 T cells are critical for prevention of acute and chronic viral infections (13) as well as for tumor eradication (14) . In recent studies, the physiological significance of TLR2 on CD8 T cell-mediated effector immune responses has been reported. Quigley et al. reported that TLR2
-/-and MyD88 -/-CD8
T cells had severely diminished clonal expansion in response to vaccinia viral (VV) infection, which involved the TLR2 co-stimulation on VV-specific CD8 T cells (8) . The study also reported that long-lived memory CD8 T cells could not develop in the absence of direct TLR2-MyD88 signaling. We also observed that TLR2 is constitutively expressed in Listeria-specific memory CD8 T cells (Fig. 1B) . Indeed, rapid Listeriaspecific memory CD8 T cell formation is affected by primary infection (15) . It may be related to TLR2 expression that is induced on Listeria-specific CD8 T cells during the primary infection time. The TLR2 expression may affect rapid expansion of the memory CD8 T cells during the secondary infection period. Our data also indicated that TLR2 co-stimulation decreased the threshold for antigen-specific signaling through TCR. We stimulated T cells with soluble anti-CD3 to provide weak TCR-mediated activation. Although, under these conditions, TLR2 signaling effectively elicited the expansion and IFN-γ production of CD8 T cells (Fig. 5) , it can be speculated that TLR2 signaling affects autoreactive CD8 T cell responses. Autoreactive T cells recognize autoantigens, which are basically presented by immature DCs that give feeble TCR signaling, resulting in ignorance or anergy (16) . Under pathogen infection conditions, TLR2 signaling enhances the direct path-way of autoreactive T cell activation by co-stimulation as well as the indirect pathway by induction of DC maturation. A number of animal models for autoimmune disease probably involve TLR signaling in their pathogenesis (17, 18) . Our data indicate that promoting the expansion and the effector function of CD8 T cells by TLR2 signaling was completely reversed by the anti-TLR2 mAb, T2.5 (Fig. 5) , the therapeutic activity of which has been reported in the sepsis model (19) . Therefore, T2.5 might be become a valuable therapeutic agent for CD8 T cell-mediated pathological conditions in the presence of TLR ligand.
Although it has been recently suggested that TLR2 could be particular in its ability to co-stimulate CD4 and CD8 T cells, in this present study, we find that its dominant effect appears to be the regulation of CD8 T cell activation. These observations suggest a potential therapeutic role for this molecule in the management of cancer and chronic infectious diseases as well as autoimmune diseases.
